A Meta-analysis Of Edaravone In The Treatment Of Acute Ischemic Stroke

Objective:To evaluate the efficacy and safety of edaravone in the treatment of acute ischemic stroke.Methods:PubMed,Web of Science,MEDLINE,Embase and Cochrane Library data were systematically retrieved,Using "Edaravone" and "human" as search terms,the literature related to Edaravone in the treatment of acute ischemic stroke was collected in the self-established database until December 30,2019.According to the inclusion and exclusion criteria,the literature was screened by two people,and the data of the included literature was extracted and methodological evaluation was carried out.In case of disagreement,the arbitration was conducted by a third party.Use RevMan5.3for statistical analysis of the collected data.Results:Eight studies were included,including 6 retrospective cohort studies and 2RCT(randomized controlled trials),with a total of 1794 patients,including 882 patients in the edaravone group(experimental group)and 912 patients in the non-edaravone group(control group).Results of the meta-analysis showed that edaravone was associated with a reduced mortality in the near term(within 30 days of onset)compared with the control group [RR = 0.75,95%ci(0.53,1.05),P=0.09],Improved neurological function recovery [RR = 1.17,95%ci(1.06,1.29),P=0.003],Reduced hospital stay [SMD =-0.12,95%ci(-0.24,-0.01),P=0.03],There was no significant difference in acute renal injury between the two groups [RR = 0.69,95%ci(0.18,2.69),P=0.60].There was no significant difference in long-term mortality [RR = 0.73,95%ci(0.46,1.18),P=0.20] and neurological recovery [RR =1.15,95%ci(0.97,1.36),P=0.10] between the two groups.Conclusion:The results showed that edaravone reduced short-term mortality,significantly improved neurological function,and shortened hospital stay in patients with acute ischemic stroke compared with the control group.However,there was no significant difference in long-term efficacy.The incidence of adverse reactions in the edaravone group was not significantly different from that in the control group and was relatively safe.The quality of the literature was rated as moderate,so the efficacy and safety of edaravone in patients with acute ischemic stroke need to be evaluated on a larger scale and with higher quality RCTS.